Figure 2.

The inhibitory effect of ATO on pancreatic cancer cell proliferation was enhanced by pre-treatment with gemcitabine or PF-3758309. Human (MiaPaCa-2 (A) and PANC-1 (B)) and murine (TB33117 (C) and KPCWT942 (D)) pancreatic cancer (PC) cells were pre-treated with gemcitabine (Gem) and PF-3758309 (PF) at concentrations indicated in the figures for 24 h, followed by 48 h treatment with arsenic trioxide (ATO). Cell proliferation was measured by the MTT assay. The values of control cells without any treatment were defined as 100%. The results were summarized from three independent experiments. *: p < 0.05; **: p < 0.01, compared to the non-treated control; #: p < 0.05, compared to Gem-pre-treatment only; $: p < 0.05, compared to PF pre-treatment only.